Articles about COVAXIN

The Ministry of External Affairs (MEA) on Friday denied reports that it had asked Bharat Biotech to address issues to avoid the cancellation of the World Health Organization's (WHO) emergency approval for its COVAXIN.

In a significant move, the Drugs Controller General of India (DCGI) on Tuesday cleared two COVID-19 vaccines for use in children aged between five and 12 years.

Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years.

COVID-19 is showing no indications of going away anytime soon, despite a decline in cases in most countries.

The Drugs Controller General of India (DCGI) on Thursday granted approval for regular market sale to India's two most prevalent COVID-19 vaccines—COVAXIN and Covishield.

Pharmaceutical firm Bharat Biotech on Monday said it plans to increase the supply of its COVID-19 vaccine COVAXIN to up to eight crore doses a month, starting February.

Prime Minister Narendra Modi on Saturday addressed the nation to announce that India will expand its nationwide COVID-19 vaccination program to adolescents aged 15-18 years next month.

COVAXIN, India's indigenous coronavirus vaccine, is 50% effective against symptomatic COVID-19, the first real-world study of its effectiveness suggests.

The government of United Kingdom has said that India's coronavirus vaccine COVAXIN will be added to its list of approved vaccines for international travelers.

India on Sunday reported nearly 11,000 new COVID-19 cases with an active caseload of 1.44 lakh, the lowest in 260 days.

The World Health Organization (WHO) on Wednesday granted Emergency Use Listing (EUL) to COVAXIN.

Australia on Monday accepted India's indigenous vaccine, COVAXIN, as a "recognized" vaccine for the purpose of travel to the country.

A technical advisory group of the World Health Organization (WHO) is reviewing data on COVAXIN and may recommend emergency use approval for the vaccine within 24 hours, an official said.

India on Wednesday reported over 14,000 new COVID-19 cases with an active caseload of 1.78 lakh, the lowest in 229 days.

India's top virologist Dr. Gagandeep Kang has said that there should not be any hurry to vaccinate children against COVID-19 as vaccine trials are ongoing and immunogenicity data is still awaited.

The World Health Organization (WHO) Monday clarified the reason behind the delay in COVAXIN's emergency use listing (EUL), stating that it is expecting more information from Bharat Biotech on its COVID-19 vaccine.

The Subject Expert Committee (SEC) on COVID-19 has recommended the approval of Bharat Biotech's COVAXIN for children aged between two and 18 years.

COVAXIN, India's indigenous vaccine against the coronavirus, will likely receive the much-awaited approval from the World Health Organization (WHO) this month.

Bharat Biotech has reportedly submitted trial data of its COVID-19 vaccine, COVAXIN, for children aged under 18 years to the Drugs and Comptroller General of India (DCGI).

A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN will be made in October, the World Health Organization has said.

India administered more than one crore coronavirus vaccine doses on Monday, taking the cumulative number of administered doses in the country to above 86 crore, according to the Union Health Ministry.

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, COVAXIN for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman, and Managing Director of Bharat Biotech International Ltd., Krishna Ella said.

Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine COVAXIN to the World Health Organization for EUL and is awaiting feedback from the global health watchdog.

NITI Aayog member Dr. VK Paul has said that India's indigenous COVID-19 vaccine COVAXIN's trial data looked promising, and the vaccine could soon get emergency-use approval from the World Health Organization (WHO) soon.

The World Health Organization has sought some more data from Russia's Gamaleya National Research Institute of Epidemiology and Microbiology, developer of COVID-19 vaccine Sputnik V for according Emergency Use Listing status to the jab.

A single dose of Bharat Biotech's COVAXIN in previously COVID-19-infected individuals elicits a similar antibody response as obtained with two doses of the vaccine in those without a previous history of the disease, according to an ICMR study.

India will likely have a COVID-19 vaccine for children by next month, Dr. Priya Abraham said in an interview.

The Drugs Controller General of India (DCGI) has approved a proposal to conduct a study on the mixing of Covishield and COVAXIN COVID-19 vaccines.

A study conducted by the Indian Council of Medical Research (ICMR) has indicated that mixing and matching of COVID-19 vaccines Covishield and COVAXIN can yield better results.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has given its go-ahead for conducting clinical trials involving the mixing and matching of Covishield and COVAXIN vaccine doses.

The Centre may soon reduce the 25% quota of COVID-19 vaccine supply for private facilities for their failure to pick up the earmarked quota.

India will miss its target to give out over 500 million (50 crore) coronavirus vaccine shots by the end of July, mainly because of low supplies of COVAXIN, its only indigenous jab so far.

Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil.

India will likely have its first coronavirus vaccine for children by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).

Bharat Biotech on Friday said it has committed to supply over 500 million doses of COVAXIN to the Centre under the countrywide immunization program.

The Centre has placed an order to procure 66 crore doses of Covishield and COVAXIN to be supplied between August and December this year, at a revised price of Rs. 205 and Rs. 215 per dose, respectively, excluding taxes, official sources said.

Hester Biosciences on Thursday said a memorandum of understanding (MoU) has been signed between Hyderabad-based vaccine maker Bharat Biotech and Gujarat COVID-19 Vaccine Consortium (GCVC) for contract manufacturing the drug substance for COVAXIN.

Coronavirus vaccination for children with the Zydus Cadila vaccine will start by September, said Dr. NK Arora, the chief of National Expert Group on Vaccine Administration.

COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.

The European Union's (EU) Digital COVID Certificate framework to allow easier, restriction-free movement of vaccinated travelers within European countries—excluding India-made Covishield and COVAXIN vaccines—comes into force on Thursday.